You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

CLINICAL TRIALS PROFILE FOR MS CONTIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ms Contin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003687 ↗ Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCIC Clinical Trials Group Phase 3 1998-06-11 RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain. PURPOSE: Randomized phase III trial to compare the effectiveness of different morphine formulations with or without dextromethorphan in treating chronic pain in patients who have advanced cancer.
NCT00009672 ↗ Pain Treatment for Sciatica Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 2001-01-30 This study will test the effectiveness of two drugs-nortriptyline and MS Contin (a type of morphine)-to treat pain caused by lumbar radiculopathy, or sciatica. Sciatica results from damage to the lumbar nerve roots, typically causing back pain and sharp, shooting pain down one or both legs. Although sciatica is common, there are no good treatments for it. Tricyclic antidepressants, such as nortriptyline, and opioids, such as morphine, have been effective in treating other kinds of pain from nerve damage. Patients between 18 and 65 years of age who have had sciatica pain daily for at least 3 months may be eligible for this study. Participants will provide a medical history and occupational and other social information. They will undergo a neurological examination, routine blood tests and an electrocardiogram and will fill out three questionnaires providing information on daily functioning and psychological well-being. This "cross-over" study consists of several parts, including a baseline study and four different treatment regimens. During each part, patients keep a daily log in which they rate their pain, record other procedures they undergo, such as injections and manipulations, and record medication side effects. In the first week of the study, patients remain on their current medications. Any antidepressants or opioids are stopped gradually before starting the drug trials. After the first week, patients go through the following four drug trials in random order: 1. Nortriptyline and inert placebo-Patients take nortriptyline in doses ranging from 25 mg. to 100 mg. and an inert placebo for morphine. (An inert placebo is a dummy pill; it looks like the test drug but has no active ingredient.) 2. MS Contin (morphine) and inert placebo-Patients take MS Contin in doses ranging from 30 mg. to 90 mg. and an inert placebo for nortriptyline. 3. Nortriptyline and MS Contin-Patients take MS Contin and nortriptyline in the same dose ranges as for each drug alone. 4. Active placebo and inactive placebo-Patients take an active placebo-in this case benztropine-and an inert placebo. An active placebo is a drug that does not work for the problem being studied but whose side effects are like those of the test drug-in this case, slight sleepiness or dry mouth. Benztropine is given at one-third the recommended dosage. For each drug regimen, the medication dose is increased gradually over 5 weeks until the maximum tolerated dose is reached. At the end of each regimen, patients are taken off the study drugs over a 12-day tapering period and are off drugs completely for another 2 days. Patients are seen by a doctor or nurse at the 7-week point in each study period. After all the drug trials are finished, patients repeat the questionnaires they filled out at the beginning of the study. Patients and their doctors will be informed of the medications that were effective in each individual's care.
NCT00288769 ↗ Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis Completed Soroka University Medical Center N/A 2006-03-01 Background: Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids . Methods: A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets. Purpose of the research: To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS). Study hypothesis: Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.
NCT00737737 ↗ Hormone Function in Men Treated for Pain With Opioids or Placebo Completed National Institute of Nursing Research (NINR) Phase 4 2008-08-01 This study will examine hormone function in men with osteoarthritis pain and how it is affected by opioid medication (such as Percocet, Vicodin, MS Contin and morphine) versus placebo. Men between 30 and 65 years of age who have had moderate to severe osteoarthritis joint pain at least 5 days a week over the past 3 months may be eligible for this study. Candidates are screened with a physical examination, x-rays, laboratory and other tests, and questionnaires about pain, mood and medical health. They are given a pain diary to complete for 2 weeks. Participants are admitted to the hospital for two 12 hour overnight stays, during each of which they provide a 24-hour urine collection and have a small blood sample drawn every 20 minutes for 12 hours (from 8:00 p.m. to 8:00 a.m.) through a catheter that remains in place in a vein. Blood pressure and pulse are monitored during this time. After the catheter is removed, subjects complete questionnaires about their pain, mood and activity. For the several weeks between the two hospitalizations, subjects take either an opioid medication or placebo, or standard medication such as motrin and naprosyn, according to random assignment to one of the three groups. All participants will be allowed to take anti-inflammatory medications and acetaminophen during this time as needed, but no other pain medications or treatments. They are monitored two or three times a week by telephone and complete a pain diary. After the second hospitalization, subjects are tapered off the study medication. After 2 to 4 weeks of stopping medication, they return for a final outpatient visit to review pain or other medical problems and to have blood drawn.
NCT01665209 ↗ Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions Completed Ranbaxy Inc. Phase 1 2006-10-01 The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide from 2 tablet products and determine if the 2 products were bioequivalent to each other.
NCT01665222 ↗ Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions Completed Ranbaxy Inc. Phase 1 2006-10-01 The study was to evaluate the relative bioavailability of morphine and morphine-6-glucuronide from 2 tablet products and determine if the 2 products were bioequivalent to each other.
NCT01734252 ↗ Argatroban in Critically Ill Patients With Heparin Resistance Completed Medical University Innsbruck Phase 2 2012-07-29 Critically ill patients with high risk for thrombosis or tromboembolic events with the presence of heparin resistance, treated at the Department for General and Surgical Critical Care Medicine of the Medical University Innsbruck, Austria will be enrolled in the study when meeting the inclusion- and exclusion criteria. If a patient meets the inclusion criteria and is recruited for the study, the patient will be randomized either to Group A or Group H. All patients have to achieve a prophylactic aPTT-target range of an aPTT-level of 45 - 60 sec (Pathromtin® SL) within 6 to 8 hours. Randomisation Group A: If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved. Randomisation Group H - Standard therapy: If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour. Therapy failure Group H: Primary target failure at Visit 3 (6-8 hours): If a patient of Group H does not achieve the target-aPTT within 6-8 hours, he/she will switch to Group A and will start with T1 (Baseline) and will follow the visits according to Group A until the final Visit 9 (T1 / day 30). Maintenance failure after Visit 3: Maintenance failure after 6-8 hours is defined as non-maintenance of the tar-get-aPTT until day 7 with a max. heparin dosage of 1.500 IU per hour. In this case, heparin therapy has to be changed to Argatroban. The patient will start with T1 (Baseline) and will follow the visits according to Group A until the final Visit 9 (day 30) counting from the Baseline of Group A. Therapy failure Group A: If a patient of Group A does not achieve the target-aPTT within 6-8 hours or cannot maintain the target-aPTT in spite of reaching the maximum dosage of 10µg/kg/min during the further study period, the patient automatically drops out of the study. The same is effective for patients who switched to the Group A after a therapy failure in Group H. General: Two hours after starting the Baseline investigations, patient's parameters in-cluding blood collections will be measured for the second time (T2). Additional measurements will be made at 6-8 hours (T3), 24 hours (T4), 48 hours (T5), 5 days (T6) after start of study drug and on day 7 before (T7) stop of study medication and 6h (T8) after stop of study medication. 30 days after inclusion in the study, a final investigation is planned (T9).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ms Contin

Condition Name

Condition Name for Ms Contin
Intervention Trials
Healthy 2
Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance 1
Radiculopathy 1
Chronic Myeloproliferative Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ms Contin
Intervention Trials
Precancerous Conditions 1
Stomatitis, Aphthous 1
Leukemia 1
Plasmacytoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ms Contin

Trials by Country

Trials by Country for Ms Contin
Location Trials
Canada 4
United States 2
Austria 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ms Contin
Location Trials
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ms Contin

Clinical Trial Phase

Clinical Trial Phase for Ms Contin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ms Contin
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ms Contin

Sponsor Name

Sponsor Name for Ms Contin
Sponsor Trials
Ranbaxy Inc. 2
NCIC Clinical Trials Group 1
National Institute of Dental and Craniofacial Research (NIDCR) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ms Contin
Sponsor Trials
Other 3
NIH 2
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ms Contin: Clinical Trials, Market Analysis, and Projections

Introduction to Ms Contin

Ms Contin, a controlled-release oral morphine formulation, is widely used for the management of moderate to severe cancer-related pain and other chronic pain conditions. Here, we will delve into the clinical trials, market analysis, and future projections for this medication.

Clinical Trials and Efficacy

Clinical trials have consistently demonstrated the efficacy and safety of Ms Contin. Studies in the United States involving nine multicenter, sequential crossover, dose titration trials showed that Ms Contin provided prolonged analgesic efficacy for patients with moderate to severe cancer-related pain. Approximately 93% of patients achieved satisfactory to excellent analgesia on a 12-hour regimen, with the remaining patients successfully maintained on an 8-hour regimen[1].

These trials also highlighted that Ms Contin was well-tolerated and had fewer side effects compared to immediate-release oral morphine and prestudy opioid analgesics. The bioequivalence and dose proportionality of different tablet strengths (15 mg, 30 mg, 60 mg, and 100 mg) were established, making these formulations therapeutically interchangeable[1].

Market Analysis

The opioid market, which includes Ms Contin, is projected to experience steady growth over the coming years. As of 2024, the global opioid market was valued at USD 23.70 billion and is expected to grow to USD 28.45 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 1.8% during the 2025-2034 period[2].

Key Drivers of Market Growth

  • Advancements in Formulations: Innovations in drug delivery methods, such as extended-release and transdermal patches, are making opioid medications more effective and easier to use. This improves patient compliance and enhances pain management[2].
  • Increasing Focus on Non-Addictive Alternatives: The development of non-addictive opioid alternatives is addressing safety concerns, making healthcare providers more inclined to prescribe these medications[2].
  • Rising Awareness of Pain Management: Growing awareness of the importance of pain management, especially in rural and underserved areas, is driving the demand for opioids like Ms Contin[2].

Regional Market Trends

  • Asia Pacific: This region is expected to experience the highest CAGR during the forecast period, driven by high population density and growing healthcare demands. Countries like Japan and China, with aging populations, are increasing the need for effective pain management solutions[2].

Market Projections

Global Market Size

The global opioid market, including Ms Contin, is anticipated to grow significantly. The market size is projected to increase from USD 24.14 billion in 2025 to USD 28.45 billion by 2034. This growth is fueled by the expanding use of opioids in various healthcare settings, including hospitals and home care[2].

Competitive Landscape

The market is characterized by strategic partnerships and mergers and acquisitions, which are enhancing market accessibility and fostering innovation. For example, partnerships like EVERSANA’s collaboration with Compai Pharma aim to expand commercialization services across the Asia Pacific region, leveraging local market insights and improving distribution networks for opioid therapies[2].

Controlled Release Drug Delivery Market

The broader controlled release drug delivery market, which includes Ms Contin, is also expected to see significant growth. This market is projected to reach over $90 billion by 2028, driven by the advantages of controlled-release drugs such as diminished side effects, reduced toxicity, and maximum precision. These factors are increasing the acceptance of controlled-release drugs among researchers and patients[3].

Challenges and Considerations

Regulatory and Supply Issues

Despite the growth projections, the opioid market faces challenges such as regulatory changes and supply disruptions. For instance, in Australia, there have been shortages and discontinuations of certain oral opioid products, including morphine oral liquids. However, efforts are being made to restore supply and provide alternative products[5].

Safety and Abuse Concerns

Ms Contin, like other opioids, carries risks of addiction, abuse, and misuse. Healthcare professionals must carefully manage these risks by reserving extended-release/long-acting opioid formulations for patients for whom alternative treatments are ineffective, not tolerated, or inadequate[4].

Key Takeaways

  • Clinical Efficacy: Ms Contin has been proven effective in managing moderate to severe cancer-related pain through multiple clinical trials.
  • Market Growth: The opioid market, including Ms Contin, is projected to grow from USD 24.14 billion in 2025 to USD 28.45 billion by 2034.
  • Regional Trends: The Asia Pacific region is expected to experience the highest CAGR due to growing healthcare demands and aging populations.
  • Innovations: Advancements in drug delivery methods and the development of non-addictive alternatives are driving market growth.
  • Challenges: Regulatory changes, supply disruptions, and safety concerns must be carefully managed.

FAQs

Q: What is Ms Contin used for?

Ms Contin is used for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic, particularly when alternative therapies are inadequate[4].

Q: What are the key benefits of Ms Contin?

Ms Contin offers prolonged analgesic efficacy, is well-tolerated, and has fewer side effects compared to immediate-release oral morphine. It is available in various tablet strengths, making it therapeutically interchangeable[1].

Q: What are the market projections for the opioid market?

The global opioid market is projected to grow from USD 24.14 billion in 2025 to USD 28.45 billion by 2034, with a CAGR of 1.8% during the 2025-2034 period[2].

Q: Which region is expected to experience the highest growth in the opioid market?

The Asia Pacific region is expected to experience the highest CAGR during the forecast period due to high population density and growing healthcare demands[2].

Q: What are the challenges facing the opioid market?

The opioid market faces challenges such as regulatory changes, supply disruptions, and safety concerns related to addiction, abuse, and misuse[4][5].

Sources

  1. The United States experience with oral controlled-release morphine ... - PubMed
  2. Opioid Market Report Size, Share & Global Trends, 2034 - Polaris Market Research
  3. Global Controlled Release Drug Delivery Market Research Report ... - Business Wire
  4. MS CONTIN Prescription & Dosage Information - eMPR
  5. About the shortage and discontinuation of oral opioid products - TGA Australia

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.